Physician profile
Luis Pineda
NPI 1538125695
$3,508.60
in general payments reported to CMS, 2019-2025
40 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,564 · 2020: $681 · 2021: $570 · 2022: $401 · 2023: $257 · 2024: $34.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $239 · Education: $52.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $238.97 |
| Education | $52.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $390.06 | 2019-2023 | Opdivo |
| Incyte Corporation | $213.06 | 2019-2021 | |
| Celgene Corporation | $202.54 | 2019-2021 | |
| Pfizer INC. | $198.04 | 2019-2023 | |
| Janssen Biotech, INC. | $173.76 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $172.23 | 2019-2023 | Cuvitru |
| Novartis Pharmaceuticals Corporation | $147.82 | 2020-2022 | |
| Seagen INC. | $145.99 | 2019-2023 | Tukysa |
| Janssen Pharmaceuticals, INC | $136.62 | 2019-2020 | |
| Lilly USA, LLC | $119.85 | 2019-2022 | |
| Dova Pharmaceuticals | $118.66 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $110.33 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $108.15 | 2019-2022 | |
| Global Blood Therapeutics, INC. | $104.07 | 2020-2022 | |
| Genzyme Corporation | $102.08 | 2019-2020 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $85.04 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $81.43 | 2019-2021 | |
| Sobi, INC | $72.53 | 2022 | |
| Csl Behring | $71.76 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $68.51 | 2019 | |
| Amgen INC. | $65.74 | 2019-2022 | |
| Gilead Sciences, INC. | $63.17 | 2019-2021 | |
| Daiichi Sankyo INC. | $62.91 | 2019-2021 | |
| Eisai INC. | $59.74 | 2019-2024 | |
| Exelixis INC. | $56.12 | 2019-2020 | |
| Puma Biotechnology, INC. | $51.72 | 2019 | |
| Epizyme, INC. | $44.26 | 2021 | |
| Rigel Pharmaceuticals, INC. | $38.06 | 2021 | |
| Agios Pharmaceuticals, INC. | $37.91 | 2023 | Pyrukynd |
| Shire North American Group INC | $33.98 | 2019 | |
| Myovant Sciences INC. | $27.18 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $21.89 | 2023 | Orgovyx |
| Amag Pharmaceuticals, INC. | $18.87 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $16.22 | 2019 | |
| Merck Sharp & Dohme LLC | $16.14 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.67 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $14.96 | 2019 | |
| Genentech USA, INC. | $14.92 | 2019 | |
| Emd Serono, INC. | $13.95 | 2020 | |
| Myriad Genetic Laboratories, INC. | $12.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Pineda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.